Brryh, thank you for trusting my opinions. I hate bureaucratic issues; I could spoil everything with a few words. Stamler is perfect for that purpose in explaining ATH434 to the FDA. It is another thing again to make a deal with big pharma. Perhaps Kempler, a psychologist, with financial experts from the board, can help us. However, outsiders may be needed. There is a lot to be done shortly. Best for me is to sit at home on my sofa.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
-0.001(6.67%) |
Mkt cap ! $138.1M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.4¢ | 1.4¢ | $10.85K | 775.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 7479968 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 16767291 | 16 |
View Market Depth
| Last trade - 10.10am 30/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |